99mTc-PSMA I&S的辐射剂量学:单中心前瞻性研究
该单中心前瞻性研究在4名健康志愿者中采用序贯γ平面显像加单次SPECT/CT的混合方法估算99mTc-PSMA I&S的剂量学,并在10例前列腺癌患者中评估其生物分布与肿瘤/本底比值。平均有效剂量为0.0055 mSv/MBq(RADAR手工法)和0.0052 mSv/MBq(OLINDA/EXM),与多数99mTc示踪剂相当,低于68Ga和18F标记药物。患者原发及转移灶均显示高摄取。
要点
- 99mTc-PSMA I&S平均有效剂量约0.0052-0.0055 mSv/MBq,与多数99mTc示踪剂相当。
- 10例前列腺癌患者原发和转移灶均高摄取,肿瘤/肌肉比值最高达110。
- 该研究为99mTc-PSMA I&S的转化和监管审批提供所需剂量学数据。
核心结论
- 99mTc-PSMA I&S的有效剂量与多数已知99mTc示踪剂相当,且低于68Ga标记和18F标记药物。
- 99mTc-PSMA I&S SPECT/CT在前列腺癌患者中显示高肿瘤/本底比值。
研究设计与样本
- 单中心前瞻性研究,在4名健康志愿者中采用序贯γ平面显像(注射后1、2、3、6、24小时)加6小时单次SPECT/CT的混合方法估算剂量学。
- 在10例前列腺癌患者中于注射后6小时SPECT/CT图像上评估生物分布、肿瘤SUVmax及肿瘤/本底比值。
主要发现
- 平均注射活度为717 MBq(范围562-828 MBq),未报告与注射相关的不良事件。
- 平均有效剂量为0.0055 mSv/MBq(RADAR手工法)和0.0052 mSv/MBq(OLINDA/EXM),全身有效剂量分别为3.33-4.42 mSv和3.11-4.23 mSv。
- 所有前列腺癌患者原发和转移灶均显示高示踪剂摄取,肿瘤/肌肉、肿瘤/膀胱和肿瘤/肠道比值范围分别为5.29-110、0.11-7.02和0.96-16.30。
临床怎么用
- 99mTc-PSMA I&S可用于平面和SPECT/CT γ显像及放射性引导手术,其剂量学数据支持向监管机构转化和审批。
- 前列腺癌患者中高肿瘤/本底比值提示该示踪剂可用于病灶显像,但需注意肿瘤/膀胱比值范围较宽(0.11-7.02)。
局限性
- 剂量学仅在4名健康志愿者中评估,样本量小。
- 生物分布和肿瘤/本底比值仅在10例前列腺癌患者中于6小时单时间点评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
99mTc-PSMA I&S is a prostate-specific membrane antigen (PSMA) tracer that can be used for planar and SPECT/CT γ-imaging and radioguided surgery. The primary aim of this study was to estimate the dosimetry of 99mTc-PSMA I&S using a hybrid method (sequential γ-planar imaging and 1 single SPECT/CT) in healthy volunteers. The secondary aim was to depict the tracer biodistribution and tumor-to-background ratios (TBRs) in patients with prostate cancer (PCa). Methods: Dosimetry of 99mTc-PSMA I&S was investigated in 4 healthy volunteers. Whole-body planar imaging was acquired at 1, 2, 3, 6, and 24 h and SPECT/CT at 6 h after tracer injection. Contours of organs were drawn on all acquisitions to determine organ activity at each time point. Absorbed dose was estimated using 2 methods: independent curve-fitting manual method (Levenberg-Marquardt-based algorithm using dose factors from RAdiation Dose Assessment Resource [RADAR] website) and OLINDA/EXM software (version 2.0; HERMES Medical Solutions). Biodistribution of 99mTc-PSMA I&S was assessed in 10 patients with PCa on SPECT/CT images at 6 h. Tumor uptake (SUVmax), and TBR (tumor SUVmax/background organ SUVmean) using muscle (T/M), bladder (T/B), and intestine (T/I) as background organs were determined. Results: The mean injected activity of 99mTc-PSMA I&S was 717 MBq (range: 562-828 MBq). No adverse events related to the injection of 99mTc-PSMA I&S were reported. The average radiation effective dose was 0.0055 mSv/MBq with the RADAR manual method and 0.0052 mSv/MBq with OLINDA/EXM. Total body effective dose ranged between 3.33-4.42 and 3.11-4.23 mSv, respectively. All PCa patients showed high tracer uptake in primary and metastatic lesions with T/M, T/B, and T/I ranging from 5.29-110, 0.11-7.02, and 0.96-16.30, respectively. Conclusion: Effective doses of 99mTc-PSMA I&S were comparable to those known for most of the 99mTc tracers and was lower than for the 68Ga-labeled and 18F-labeled agents. 99mTc-PSMA I&S SPECT/CT showed high TBR in PCa patients. This study can provide required data for translation and approval of 99mTc-PSMA I&S by regulatory agencies.
引用
- Urbán S, Meyer C, Dahlbom M, et al. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study. J Nucl Med. 2020. PMID: 33277398. doi:10.2967/jnumed.120.253476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。